That's true, but it depends what is needed to get the drug into Asia. If further trials etc are needed in Asia i can see those funded by a new partner.
If not, then I can see Neuren waiting until P3 results to do a deal, as I don't see partners willing to put up anything close to $100m upfront for a drug that still has a possibility of failing P3.
NEU Price at posting:
$1.46 Sentiment: Hold Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)